Camurus AB
CAMX
Classement en actions
#4014
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Prix de l'action
$67.58
Capitalisation boursière
$4.02B
Changement (1 jour)
0.00%
Changement (1 an)
-2.99%
Pays
SE
Échange Camurus AB (CAMX)
Catégorie
Healthcare
Ratio P/E pour Camurus AB (CAMX)
Ratio P/E au October 2026 TTM : 58.91
Selon les derniers rapports financiers et le cours de l'action de Camurus AB, le ratio P/E actuel (TTM) est de 58.91. À la fin de l’année 2024, le P/E de l’entreprise était de 76.57.
Historique du ratio P/E pour Camurus AB de 2011 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 58.91 | 18.77% |
| 2025 | 49.60 | -35.23% |
| 2024 | 76.57 | 10.69% |
| 2023 | 69.18 | -72.37% |
| 2022 | 250.39 | -375.80% |
| 2021 | -90.79 | 54.65% |
| 2020 | -58.70 | 333.11% |
| 2019 | -13.55 | 30.62% |
| 2018 | -10.38 | -62.11% |
| 2017 | -27.39 | -48.82% |
| 2016 | -53.51 | 335.39% |
| 2015 | -12.29 | -124.04% |
| 2014 | 51.13 | 105.26% |
| 2013 | 24.91 | -86.58% |
| 2012 | 185.63 | 0.00% |
| 2011 | 0.00 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -51.14% |
US
|
|
| -28.36 | -148.14% |
US
|
|
| -25.99 | -144.12% |
AU
|
|
| 31.22 | -47.01% |
NL
|
|
| 17.49 | -70.31% |
BE
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.